

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
CTUMM.001CP2APPLICATION NO.
09/776,232INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(SEE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Kündig, et al.FILING DATE
February 2, 2001GROUP
Unknown**COPY**

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
|---------------------|----|-----------------|----------|--------------------|-------|----------|---------------------------------|
| PJA | 1 | 3,604,417 | 9/14/71 | Stolzenberg et al. | | | |
| | 2 | 3,732,865 | 5/15/73 | Higuchi, et al. | | | |
| | 3 | 3,760,804 | 9/25/73 | Higuchi, et al. | | | |
| | 4 | 3,760,805 | 9/25/73 | Higuchi | | | |
| | 5 | 3,780,984 | 9/25/73 | Theeuwes | | | |
| | 6 | 3,929,132 | 12/30/75 | Higuchi | | | |
| | 7 | 3,987,790 | 10/26/76 | Eckenhoff, et al. | | | |
| | 8 | 3,995,631 | 12/7/76 | Higuchi, et al. | | | |
| | 9 | 3,995,632 | 12/7/76 | Nakano, et al. | | | |
| | 10 | 4,034,756 | 7/12/77 | Higuchi, et al. | | | |
| | 11 | 4,203,440 | 5/20/80 | Theeuwes | | | |
| | 12 | 4,286,067 | 8/25/81 | Theeuwes | | | |
| | 13 | 4,300,558 | 11/12/81 | Eckenhoff et al. | | | |
| | 14 | 4,304,232 | 12/8/81 | Michaels | | | |
| | 15 | 4,340,048 | 7/20/82 | Eckenhoff | | | |
| | 16 | 4,340,054 | 7/20/82 | Michaels | | | |
| | 17 | 4,350,271 | 9/21/82 | Eckenhoff | | | |
| | 18 | 4,367,741 | 1/11/83 | Michaels | | | |
| | 19 | 4,435,173 | 3/6/84 | Siposs et al. | | | |
| | 20 | 4,439,199 | 3/27/84 | Amkraut et al. | | | |
| | 21 | 4,450,198 | 5/22/84 | Michaels | | | |
| | 22 | 4,455,145 | 6/19/84 | Theeuwes | | | |
| | 23 | 4,474,575 | 10/2/84 | Eckenhoff, et al. | | | |
| | 24 | 4,498,843 | 2/12/85 | Schneider et al. | | | |
| | 25 | 4,528,569 | 7/2/85 | Bernardi | | | |
| ✓ | 26 | 4,552,651 | 11/12/85 | Sandbrook, et al. | | | |

EXAMINER


DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

| | | |
|--|------------------------------------|-------------------------------|
| FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | ATTY. DOCKET NO. CTLIIMM.001CP2 | APPLICATION NO. 09/776,232 |
| | APPLICANT Köndig, et al. | |
| | FILING DATE February 2, 2001 | GROUP Unknown 1644 |


| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|----------|--------------------|-------|----------|---------------------------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
| PJK | 27 | 4,561,856 | 12/31/85 | Cochran | | | |
| | 28 | 4,619,652 | 10/28/86 | Eckenhoff, et al. | | | |
| | 29 | 4,643,723 | 2/17/87 | Smit | | | |
| | 30 | 4,753,651 | 6/28/88 | Eckenhoff | | | |
| | 31 | 4,767,626 | 8/30/88 | Hutchinson et al. | | | |
| | 32 | 4,838,862 | 6/13/89 | Baker et al. | | | |
| | 33 | 4,855,141 | 8/8/89 | Eckenhoff, et al. | | | |
| | 34 | 4,865,598 | 9/12/89 | Eckenhoff | | | |
| | 35 | 4,865,845 | 9/12/89 | Eckenhoff, et al. | | | |
| | 36 | 4,872,873 | 10/10/89 | Zingerman | | | |
| | 37 | 4,898,582 | 2/6/90 | Faste | | | |
| | 38 | 4,908,433 | 3/13/90 | Mertlesmann et al. | | | |
| | 39 | 4,929,233 | 5/29/90 | Roth et al. | | | |
| | 40 | 4,963,141 | 10/16/90 | Eckenhoff | | | |
| | 41 | 4,976,966 | 12/11/90 | Theeuwes, et al. | | | |
| | 42 | 5,017,381 | 5/21/91 | Maruyama, et al. | | | |
| | 43 | 5,023,088 | 6/11/91 | Wong et al. | | | |
| | 44 | 5,030,216 | 7/9/91 | Theeuwes et al. | | | |
| | 45 | 5,034,229 | 7/23/91 | Magruder, et al. | | | |
| | 46 | 5,037,420 | 8/6/91 | Magruder, et al. | | | |
| | 47 | 5,057,318 | 10/15/91 | Magruder, et al. | | | |
| | 48 | 5,059,423 | 10/22/91 | Magruder, et al. | | | |
| | 49 | 5,110,596 | 5/5/92 | Magruder, et al. | | | |
| | 50 | 5,110,597 | 5/5/92 | Wong, et al. | | | |
| | 51 | 5,135,498 | 8/4/92 | Kam, et al. | | | |
| | 52 | 5,135,523 | 8/4/92 | Magruder, et al. | | | |

| | |
|--|----------------------------|
| EXAMINER PJK | DATE CONSIDERED 5/12/04 |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |

| | | | |
|---|--|----------------------------------|-------------------------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. CTUMM.001CP2 | APPLICATION NO. 09/778,232 |
|  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | | APPLICANT Kündig, et al. | |
| | | FILING DATE February 2, 2001 | GROUP Unknown <i>7644</i> |


| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----|-----------------|----------|------------------|-------|----------|---------------------------------|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE (IF APPROPRIATE) |
| <i>PAK</i> | 53 | 5,137,727 | 8/11/92 | Eckenhoff | | | |
| | 54 | 5,169,390 | 12/8/92 | Athayde, et al. | | | |
| | 55 | 5,174,999 | 12/29/92 | Magruder, et al. | | | |
| | 56 | 5,209,748 | 5/11/93 | Balaban, et al. | | | |
| | 57 | 5,221,278 | 6/22/93 | Linkwitz, et al. | | | |
| | 58 | 5,223,265 | 6/29/93 | Wong | | | |
| | 59 | 5,257,987 | 11/2/93 | Athayde et al. | | | |
| | 60 | 5,286,254 | 2/15/94 | Shapland et al. | | | |
| | 61 | 5,304,165 | 4/19/94 | Haber et al. | | | |
| | 62 | 5,368,562 | 11/29/94 | Blomquist et al. | | | |
| | 63 | 5,478,558 | 12/26/95 | Elliott et al. | | | |
| | 64 | 5,496,360 | 3/5/96 | Hoffmann et al. | | | |
| | 65 | 5,580,859 | 12/03/96 | Felgner et al. | | | |
| | 66 | 5,589,466 | 12/31/96 | Felgner et al. | | | |
| | 67 | 5,679,647 | 10/21/97 | Carson et al. | | | |
| | 68 | 5,698,396 | 12/16/97 | Pfreundschuh | | | |
| | 69 | 5,733,548 | 03/31/98 | Restifo et al. | | | |
| | 70 | 5,744,316 | 4/28/98 | Lethe et al. | | | |
| | 71 | 5,747,269 | 5/5/98 | Rammensee et al. | | | |
| | 72 | 5,846,540 | 12/08/98 | Restifo et al. | | | |
| | 73 | 5,858,187 | 01/05/99 | Restifo et al. | | | |
| | 74 | 5,962,428 | 10/05/99 | Carrano et al. | | | |
| <i>✓</i> | 75 | 6,037,135 | 03/14/00 | Kubo et al. | | | |


| | |
|--|-----------------------------------|
| EXAMINER <i>[Signature]</i> | DATE CONSIDERED <i>5/12/04</i> |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |

| | | | |
|---|--|-----------------------------------|-------------------------------|
| FORM PTO-1449 | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. CTLMIM.001CP2 | APPLICATION NO. 09/776,232 |
|  <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p> | | APPLICANT Kündig, et al. | |
| | | FILING DATE February 2, 2001 | GROUP Unknown 1644 |

| FOREIGN PATENT DOCUMENTS | | | | | | | | |
|--------------------------|----|-----------------|----------|---------|-------|----------|-------------|----|
| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | YES | NO |
| PJT | 76 | 2,147,863 | 05/26/94 | Canada | | | | |
| | 77 | 74899 | 08/13/97 | Ireland | | | | |
| | 78 | EP 93/03175 | 04/06/95 | PCT | | | | |
| | 79 | WO 92/21033 | 11/26/92 | PCT | | | | |
| | 80 | WO 95/17187 | 06/25/95 | PCT | | | | |
| | 81 | WO 96/01429 | 01/18/96 | PCT | | | | |
| | 82 | WO 96/27008 | 09/06/96 | PCT | | | | |
| | 83 | WO 96/40209 | 12/19/96 | PCT | | | | |
| | 84 | WO 98/13489 | 04/02/98 | PCT | | | | |
| | 85 | WO 98/14464 | 04/09/98 | PCT | | | | |
| | 86 | WO 98/27963 | 07/02/98 | PCT | | | | |
| | 87 | WO 98/43611 | 10/08/98 | PCT | | | | |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) | |
|---------------------|--|--|
| PJT ✓ | 88 | Bachman, M.F., et al. (1994) In vitro vs. in vivo assays for the assessment of T-and B cell function. Curr. Opin. Immunol. 6:320-326. |
| ✓ | 89 | Cleland, J.L., et al. (1994) Formulation and delivery of proteins and peptides. American Chemical Society, Acs Symposium Series No. 567. |
| ✓ | 90 | Courvalin, P. et al. (1995) Life Sci. 318:1207-1212. |
| ✓ | 91 | Dietrich, G. et al. (1998) Biotechnology 16:181-185. |
| ✓ | 92 | Durrant LG (1997) Cancer vaccines. Anti-cancer drugs. 8:727-733. |
| ✓ | 93 | Grohmann, U. et al. (1991) Intrasplenic immunization for the induction of humoral and cell-mediated immunity to nitrocellulose-bound antigen. Journal of Immunological Methods. 137:9-15. |
| ✓ | 94 | Haynes, B. F. et al. (1996) Toward an understanding of the correlates of protective immunity to HIV infection. Science. 271:324-327. |
| ✓ | 95 | Inaba, K., et al. (1992) Identification of proliferating dendritic cell precursors in mouse blood. Journal of Experimental Medicine. 175:1157-1167. |
| ✓ | 96 | Jager, E., et al. (1996) Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer. 67:54-62. |
| ✓ | 97 | Jager E. et al. (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding Peptide Epitopes. J.Exp.Med. 187:265-270. |
| ✓ | 98 | Kündig, T.M. et al. (1992) Skin test to assess virus-specific cytotoxic T-cell activity. Proc. Natl. Acad. Sci. 89:7757-7761. |
| ✓ | 99 | Kündig, T.M. et al. (1995) Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science. 268:1343-1347. |

| | |
|--|-----------------|
| EXAMINER | DATE CONSIDERED |
|  | 5/12/04 |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |

| | | | |
|--|--|---|-------------------------------|
| FORM PTO-1449  | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. CTLMM.001CP2 | APPLICATION NO. 09/776,232 |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY) | | APPLICANT Kündig, et al. FILING DATE February 2, 2001 GROUP Unknown 1644 | |

| EXAMINER INITIAL | OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.) |
|---------------------|--|
| ✓ | 100 Kundig, T.M. et al. (1996) On the role of antigen in maintaining cytotoxic T cell memory. Proc. Natl. Acad. Sci. 93:9716-9723. |
| ✓ | 101 Moskopidis D. et al. (1995) Immunobiology of Cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. Journal of Virology. 69:4:2187-2193. |
| ✓ | 102 Oehen S. et al. (1992) Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen. J.Exp.Med. 176:1273-1281. |
| ✓ | 103 Oldstone, M. et al. (1995) Discriminated selection among viral peptides with the appropriate anchor residues: Implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. Journal of Virology. 69:12:7423-7429. |
| ✓ | 104 Pantaleo G. et al. (1997) Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc. Natl. Acad. Sci. 94:9848-9853. |
| ✓ | 105 Peters, R.I. et al. (1984) Tryptophan and serotonin metabolism after sustained tryptophan infusion. Neurochem. Int. 6:5:685-691. |
| ✓ | 106 Pfeiffer, et al. "Insulin Pump Therapy" 3.1 to 3.2.4 pg. 14-33 |
| ✓ | 107 Puccetti P. et al. (1994) Use of skin test assay to determine tumor-specific CD8+ T cell reactivity. Eur. J. Immunol. 24:1446-1452. |
| ✓ | 108 Rammensee, H.G. et al. (1985) MHC ligands and peptide motifs: first listing. Immunogenetics.41:178-228. |
| ✓ | 109 Rammensee, H.G. et al. (1997) MHC ligands and peptide motifs. Landes Bioscience Austin Texas. Chapter 4:217-369. |
| ✓ | 110 Remington (1985) The science and practice of pharmacy, Nineteenth Edition: Chapters 86-88. |
| ✓ | 111 Santus G. et al. (1995) Osmotic drug delivery: a review of patent literature. Journal of Controlled Release. 35:1-21. |
| ✓ | 112 Simard, John J.L., et al.; 09/560,465; April 28, 2000; EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS. |
| | 113 Simard, John J.L., et al.; 09/561,074; April 28, 2000; METHOD OF EPITOPE DISCOVERY. |
| | 114 Simard, John J.L., et al.; 09/561,571; April 28, 2000; EPITOPE CLUSTERS. |
| | 115 Simard, John J.L., et al.; 09/561,572; April 28, 2000; EXPRESSION VECTORS ENCODING EPITOPES OF TARGET-ASSOCIATED ANTIGENS. |
| ✓ | 116 Sizemore, D.R. et al. (1995) Science 270:299-302. |
| ✓ | 117 Speiser, D.E. et al. (1997) Self antigens expressed by solid tumors do not efficiently stimulate naïve or activated T cells: implications for immunotherapy. J. Exp. Med. 186:645-653. |
| ✓ | 118 Steinman R.M. (1991) The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:271-296. |
| ✓ | 119 Wiseman C. et al. (1993) Clinical responses to intralymphatic whole-cell melanoma vaccine augmented by in vitro incubation with alpha-interferon. Annals of the New York Academy of Sciences. 690:388-391. |
| ✓ | 120 Wiseman C.L. et al. (1989) Clinical responses with active specific intralymphatic immunotherapy for cancer - A phase I-II trial. The Western Journal of Medicine. 151:283-288. |
| ✓ | 121 Young J. W. et al. (1996) Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J.Exp.Med. 183:7-11. |
| ✓ | 122 Zipkin I. (1998) Cancer vaccines. BioCentury. 8:A1-A6. |

| | |
|--|-------------------------|
| EXAMINER | DATE CONSIDERED 5/12/04 |
| *EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT. | |